Dr. Sarah Sammons

Join Dr. Sarah Sammons, a medical oncologist at Dana-Farber Cancer Institute, as she discusses groundbreaking insights into HER2-positive breast cancer treatment. She explores treatment options for early-stage HER2-positive patients, including key findings from the APT trial. The conversation shifts to the latest data from the PATINA trial, revealing its implications for metastatic cases. Dr. Sammons also highlights innovations like T-DXd for brain metastases and the management of toxicities with neoadjuvant therapies. Tune in for practical pearls that could transform treatment decisions!